The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

The FDA granted the approval of Hympavzi to Pfizer Inc.

10月11日，黑龙江省医保局官微曝光了3例违法违规使用医疗保障基金的典型案例，涉及串换项目收费、重复收费、超标准收费、过度检查、将不属于医疗保障基金支付范围的医药费用纳入医疗保障基金结算等违法违规行为。

【来源：人民日报健康客户端】10月11日，美国食品药品监督管理局（FDA）批准辉瑞药品Hympavzi（marstacimab）用于常规预防或减少12岁及以上血友病A和血友病B成人和儿童患者的出血，这些患者体内不含凝血因子VIII与IX抑制剂（中和抗体）。

The US Food and Drug Administration (FDA) on Friday approved US pharma giant Pfizer’s Hympavzi (marstacimab-hncq) for routine ...